{"id":"tamsulosin-and-tadalafil","safety":{"commonSideEffects":[{"rate":"5-15","effect":"Headache"},{"rate":"5-10","effect":"Dizziness"},{"rate":"3-8","effect":"Dyspepsia"},{"rate":"3-5","effect":"Nasal congestion"},{"rate":"2-5","effect":"Back pain"},{"rate":"2-4","effect":"Orthostatic hypotension"},{"rate":"5-10","effect":"Retrograde ejaculation"}]},"_chembl":{"chemblId":"CHEMBL1200914","moleculeType":"Small molecule","molecularWeight":"444.98"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Tamsulosin is an alpha-1A selective antagonist that reduces smooth muscle tone in the prostate and bladder neck, improving urine flow and reducing lower urinary tract symptoms in benign prostatic hyperplasia. Tadalafil is a phosphodiesterase-5 inhibitor that enhances nitric oxide signaling, increasing cGMP levels to relax smooth muscle in the corpus cavernosum and lower urinary tract tissues, improving erectile function and LUTS. The combination addresses both erectile dysfunction and benign prostatic hyperplasia symptoms.","oneSentence":"Tamsulosin selectively blocks alpha-1A adrenergic receptors in the prostate to relax smooth muscle, while tadalafil inhibits phosphodiesterase-5 to increase cGMP and improve erectile function and lower urinary tract symptoms.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:11:03.759Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Benign prostatic hyperplasia with lower urinary tract symptoms"},{"name":"Erectile dysfunction associated with benign prostatic hyperplasia"}]},"trialDetails":[{"nctId":"NCT07447518","phase":"EARLY_PHASE1","title":"Double j Stent Related Symptoms","status":"COMPLETED","sponsor":"Kafrelsheikh University","startDate":"2022-09-22","conditions":"Lower Urinary Tract Symptoms","enrollment":535},{"nctId":"NCT03229889","phase":"PHASE4","title":"Trial of Tadalafil, Tamsulosin and Combination for Access Sheath Deployment","status":"COMPLETED","sponsor":"University of California, Irvine","startDate":"2017-06-07","conditions":"Nephrolithiasis","enrollment":220},{"nctId":"NCT06809205","phase":"PHASE4","title":"Efficacy and Safety of Tadalafil, Tamsulosin, and Their Combinations in Treating Lower Urinary Tract Symptoms in BPH Patients with Prostate Volumes ≤ 40 Ml: a Prospective Comparative Study","status":"COMPLETED","sponsor":"Fayoum University Hospital","startDate":"2023-04-20","conditions":"BPH with Other Lower Urinary Tract Symptoms","enrollment":95},{"nctId":"NCT06707181","phase":"PHASE3","title":"Comparative Study for Medical Therapy for Lower Ureteral Stones","status":"COMPLETED","sponsor":"Beni-Suef University","startDate":"2023-11-01","conditions":"Lower Ureteral Stones","enrollment":180},{"nctId":"NCT06491108","phase":"PHASE3","title":"Medications for Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia","status":"RECRUITING","sponsor":"Tanta University","startDate":"2024-06-01","conditions":"Enlarged Prostate With Lower Urinary Tract Symptoms","enrollment":150},{"nctId":"NCT05818670","phase":"PHASE4","title":"Comparison Between Tamsulosin and Tadalafil in Management of Benign Prostatic Hyperplasia Long Term Study","status":"COMPLETED","sponsor":"Mansoura University","startDate":"2020-11-11","conditions":"BPH","enrollment":160},{"nctId":"NCT05537272","phase":"PHASE4","title":"The Efficacy of Tamsulosin and Tadalafil Compared to Placebo in the Treatment and Prevention of Urinary Disorders After Transperineal Prostate Biopsy","status":"UNKNOWN","sponsor":"University Hospital of Split","startDate":"2022-09-01","conditions":"Lower Urinary Tract Symptoms, Voiding Disorders, Pain","enrollment":120},{"nctId":"NCT05494567","phase":"PHASE4","title":"Efficacy of Tadalafil/Solifenacin VS Tamsulosin/Solifenacin Combination Therapy for BPH/OAB","status":"UNKNOWN","sponsor":"Mansoura University","startDate":"2021-11-08","conditions":"Benign Prostatic Hyperplasia, Overactive Bladder","enrollment":60},{"nctId":"NCT05236634","phase":"NA","title":"(Phosphodiesterase 5 Inhibitors & α-blockers): Single Versus Combined Therapy in Benign Prostatic Hyperplasia","status":"UNKNOWN","sponsor":"Assiut University","startDate":"2022-05-01","conditions":"Benign Prostatic Hyperplasia","enrollment":120},{"nctId":"NCT04383093","phase":"","title":"Tadalafil Plus Tamsulosin for Male LUTS and ED","status":"COMPLETED","sponsor":"University of Florence","startDate":"2017-01-01","conditions":"Prostatic Hyperplasia, Benign, Lower Urinary Tract Symptoms, Erectile Dysfunction","enrollment":75},{"nctId":"NCT03246880","phase":"PHASE3","title":"Clinical Trial To Evaluate the Efficacy and Safety of CKD-397 in Benign Prostatic Hyperplasia Patients","status":"COMPLETED","sponsor":"Chong Kun Dang Pharmaceutical","startDate":"2015-09","conditions":"Benign Prostatic Hyperplasia","enrollment":455},{"nctId":"NCT01937871","phase":"PHASE3","title":"A Study of Tadalafil in Men With Benign Prostatic Hyperplasia (BPH) and Erectile Dysfunction (ED)","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2013-09","conditions":"Benign Prostate Hyperplasia, Erectile Dysfunction","enrollment":909},{"nctId":"NCT02862483","phase":"PHASE3","title":"The Efficacy and Safety of the Combination of Tamsulosin and Tadalafil in Men With Lower Urinary Tract Symptoms Due to Benign Prostatic Hyperplasia and Erectile Dysfunction","status":"UNKNOWN","sponsor":"IlDong Pharmaceutical Co Ltd","startDate":"2016-03","conditions":"Benign Prostatic Hyperplasia, Erectile Dysfunction","enrollment":330},{"nctId":"NCT02645890","phase":"PHASE1","title":"Study to Compare the Safety and Pharmacokinetics of CKD-397","status":"COMPLETED","sponsor":"Chong Kun Dang Pharmaceutical","startDate":"2015-11","conditions":"Benign Prostatic Hyperplasia","enrollment":36},{"nctId":"NCT02247518","phase":"PHASE1","title":"CKD-397 Drug-drug Interaction Study (A)","status":"COMPLETED","sponsor":"Chong Kun Dang Pharmaceutical","startDate":"2014-09","conditions":"Healthy","enrollment":16},{"nctId":"NCT02247505","phase":"PHASE1","title":"CKD-397 Drug-drug Interaction Study (B)","status":"COMPLETED","sponsor":"Chong Kun Dang Pharmaceutical","startDate":"2014-09","conditions":"Healty Male Volunteers","enrollment":29},{"nctId":"NCT02239484","phase":"PHASE1","title":"Evaluating a Pharmacokinetic Drug Interaction Between Tadalafil and Tamsulosin","status":"COMPLETED","sponsor":"Hanmi Pharmaceutical Company Limited","startDate":"2014-03","conditions":"Erectile Dysfunction, Benign Prostatic Hyperplasia","enrollment":30},{"nctId":"NCT00970632","phase":"PHASE3","title":"A Study of Tadalafil in Men With Benign Prostatic Hyperplasia","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2009-10","conditions":"Benign Prostatic Hyperplasia (BPH)","enrollment":511},{"nctId":"NCT00861757","phase":"PHASE3","title":"Multinational Study to Evaluate Tadalafil in Asian Men With Signs and Symptoms of Benign Prostatic Hyperplasia","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2009-03","conditions":"Benign Prostatic Hyperplasia","enrollment":612},{"nctId":"NCT00540124","phase":"PHASE2","title":"Pilot Study Investigating Safety and Efficacy of Tadalafil as Treatment for Benign Prostatic Hyperplasia (BPH) in Asian Men","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2007-10","conditions":"Benign Prostatic Hyperplasia","enrollment":151}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":129,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Group C"],"phase":"marketed","status":"active","brandName":"Tamsulosin and Tadalafil","genericName":"Tamsulosin and Tadalafil","companyName":"Fayoum University Hospital","companyId":"fayoum-university-hospital","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Tamsulosin selectively blocks alpha-1A adrenergic receptors in the prostate to relax smooth muscle, while tadalafil inhibits phosphodiesterase-5 to increase cGMP and improve erectile function and lower urinary tract symptoms. Used for Benign prostatic hyperplasia with lower urinary tract symptoms, Erectile dysfunction associated with benign prostatic hyperplasia.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}